Chihiro Tomoyasu

Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines

Kazuya Takahashi, Takeshi Inukai, Toshihiko Imamura et al. · PLoS ONE · 2017 · 44 citations · Full text

Mixed-phenotype Acute Leukemia, Apoptosis, Immunology +16

BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?

Sachiko Kawashima‐Goto, Toshihiko Imamura, Chihiro Tomoyasu et al. · PLoS ONE · 2015 · 25 citations · Full text

Bcl2 Inhibitor, Psl Resistance, Hematological Malignancy +13

Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes

Chihiro Tomoyasu, Toshihiko Imamura, Toshihiro Tomii et al. · International Journal of Hematology · 2018 · 15 citations

Hematological Malignancy, Genetic Subtypes, Tumor Heterogeneity +12

OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells

Chihiro Tomoyasu, Ken Kikuchi, Daisuke Kaneda et al. · Oncology Reports · 2018 · 12 citations · Full text

The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of <i>NOXA</i>

Yohei Sugimoto, Yoshiki Katsumi, Tomoko Iehara et al. · Molecular Cancer Therapeutics · 2020 · 11 citations · Full text